Sanofi India Ltd
NSE: SANOFI BSE: 500674
₹2966.20
-16.60 (0.56%)
Sat, 24 Oct 2026, 06:06 am
Market Cap (in Cr)6819.76
PE Ratio21.10
Dividend4.15
Health Technology
Pharmaceuticals: Major
24.5KSanofi India Ltd Company History
1956
- Incorporated as Hoechst Fedco Pharma Pvt. Ltd. on March 31.
- Established with financial and technical collaboration of Hoechst AG.
- Signed Licence and Technical Collaboration Agreement on July 11 granting HOECHST name and trademarks use.
- Issued 10,000 preference and 10,000 equity shares to promoters; 5,000 preference and 9,867 equity as rights.
1957
- Set up manufacturing unit at Mulund for basic drugs and intermediates.
1961
- Deleted 'Private' from name as deemed public limited company under Section 41-A.
- Issued 28,133 equity shares as rights.
1967
- Issued 37,800 bonus equity shares in 3:5 proportion.
- Issued 17,000 equity shares as rights.
1969
- Issued 57,222 bonus equity shares in 49:100 proportion.
1974
- Issued 164,990 bonus equity shares in 94:100 proportion.
1979
- Issued 170,256 bonus equity shares in 1:2 proportion.
1982
- Set up manufacturing unit at Kandla Free Trade Zone for exports.
- Issued 255,384 bonus equity shares in 1:2 proportion.
1984
- Issued 119,538 equity shares at Rs 100 premium; preferential allotment to associates and employees; balance to public.
1986
- Revalued land, buildings, plant, and machinery as of December 31.
- Incorporated subsidiary Hoechst Nepal Pvt. Ltd. in February.
1987
- Commissioned Haemaccel plant extension at Mulund and fine chemicals plant at Ankleshwar.
- Obtained industrial licence for Petoxifylline, Ciclopiroxolamine, diagnostic reagents.
1988
- Received industrial licence for RABIPUR rabies vaccine.
- Obtained MRTP Act approval for hybrid seeds undertaking.
- Issued 230,000 14% secured redeemable NCDs on private placement.
1989
- Re-entered antifungal market with BATRAFEN.
- Introduced insecticide HOSTATHION and poultry promoter FLAVOMYCIN.
- Commissioned pharma formulation plant at Ankleshwar and liquid injectables line at Mulund.
1990
- Introduced TARIVID, AVIL retard, TABLON, FLUROFEN.
- Received letters of intent and industrial licence for multiple products.
1991
- Introduced herbicide Klass, Butox, Tolzan.
- Received industrial licences and letters of intent for multiple products.
- Revalued freehold land and buildings; transferred surplus to reserves.
1992
- Introduced antihypertensive Rene Dil and anti-ulcer Rotane.
- Received industrial licences and letters of intent for multiple products.
- Commissioned additional super centrifuge for PCEC plant in Ankleshwar.
1993
- Issued 1,938,411 equity shares at Rs 60 premium to Hoechst AG, increasing stake to 51%.
1994
- Introduced Cardace, Typhoral oral typhoid vaccine, Candur-R antirabies vaccine.
- Transferred agrochemicals division to Hoechst Schering Agrfoo Ltd via scheme of arrangement.
- Issued 11,515,311 bonus equity shares in 1:1 proportion.
1995
- Launched INSUMAN human insulin and Floxidin antibiotic.
- Closed foot and mouth disease vaccine and Candur DHL plants.
- Amalgamated Roussel India Ltd; name changed to Hoechst Marion Roussel Ltd effective January 1, 1996.
1996
- Launched Insuman anti-diabetic drug.
- Suspended Baralgan production per government order.
- Expanded Rabipur plant capacity to 3.5 million doses per annum.
- Proposed joint venture with Chiron for vaccines.
1997
- Proposed introduction of Frisium, Amaryl, Cefrom, Targocil.
- Hoechst Roussel bought out stakes in Hoechst Roussel Vet Private Limited.
- Formed 50:50 JV Hoechst-Huabei Pharmaceuticals Co. Ltd.
1998
- Entered joint venture with Chiron Corporation in April for Rabipur manufacture and vaccine distribution rights.
- Purchased 33.33% stake in Roussel India from Roussel Laboratories UK.
- Planned transfer of animal healthcare business to JV with Chiron.
1999
- Launched voluntary retirement scheme at Mulund factory.
2000
- Planned introduction of Allegra and Tavanic variants.
- Ramesh Subrahmanian re-designated deputy managing director.
- Implemented employee stock option schemes.
- Acquired 2,955,608 equity shares of Rhone-Poulenc Rorer at Rs 15 per share.
- Hoechst Marion Roussel renamed Aventis Pharma.
2002
- Mr. W. Wagner appointed Director.
- Bombay High Court sanctioned amalgamation of Rhone-Poulenc Rorer with Aventis Pharma.
- Aventis Pharma sales increased 16% to Rs 261cr.
2003
- Aventis Pharma filed lawsuit alleging patent infringement.
- CRISIL withdrew AAA rating for Rs 30cr NCD issue.
- Mr. M.G. Rao and Dr. S. Bhattacharya appointed Alternate Directors.
- Ramesh Subramanian appointed VP Respiratory Sales for US regions.
2007
- Aventis Pharma appointed Mr. Eric Le-Bris as Additional Director.
- Aventis Pharma appointed Mr. S.C. Ghoge as Wholetime Director.
2008
- Aventis Pharma launched Lantus insulin in Solostar pen.
2010
- Mr. M. Dargentolle appointed Director.
- Mr. J. M. Georges and Mr. F. X. Duhalde appointed Additional Directors.
2011
- Aventis Pharma acquired nutraceutical business of Universal Medicare Private Limited.
- Sanofi India launched Fun Center for pediatric patients in Bangalore with HealthCare Global.
2012
- Sanofi India launched reusable insulin pen AllStar.
- Sanofi appointed Susheel Umesh as Head of Commercial Operations for Pharma in India.
- Company changed name from Aventis Pharma Ltd to Sanofi India Ltd.
2013
- Sanofi India launched Combiflam Plus.
- Sanofi tied up with IDF and PHFI against diabetes in children.
- Sanofi partnered with PVR Nest for Healthy Children initiative.
- Madhuri Dixit created diabetes dance step for Sanofi What Step Will You Take Today initiative.
- Sanofi inked pact with Suzlon Energy for renewable energy.
2014
- Sanofi partnered with Emcure for marketing and distribution of oncology portfolio in India.
2015
- Sanofi delivered 4 lakh Shan5 vaccine doses to Gwalior and Jabalpur.
- Sanofi India shifted registered office to Saki Vihar Road, Powai, Mumbai.
- Sanofi and RSSDI held Mega Walkathon for diabetes control in Lucknow.
2016
- Sanofi India collaborated with NIPER Kolkata for academic excellence and research.
2017
- Sanofi India launched Combiflam ICYHOT pain relief.
- 23 young people with type 1 diabetes scaled Maharashtra’s highest peak in first T1D Challenge.
2018
- Sanofi launched new diabetes treatment insulin in India.
- Sanofi launched multiple sclerosis treatment drug in India.
- Sanofi launched once-daily oral tablet Aubagio in India.
2019
- Sanofi India partnered to reduce diabetes burden on state's health exchequer.
2020
- Sanofi Pasteur launched VaxLine in India.
- Sanofi India launched Allergy Free.
- Sanofi Pasteur launched Tetraxim DTaP booster vaccine for preschoolers in India.
2021
- Sanofi India announced sale and transfer of Nutraceuticals business to Universal Nutriscience.
- Sanofi and GSK received approval for Phase 3 trial of COVID-19 vaccine candidate in India.
2023
- Sanofi received marketing approval for diabetes drug Soliqua in India.
2024
- Sanofi announced expansion of its Global Capability Centre in Hyderabad.
- Sanofi received marketing authorization for Beyfortus in India against RSV.
- Sanofi and Cipla announced exclusive distribution partnership for CNS portfolio in India.
